Abstract
The role of cAMP in mediating prostaglandin E2 (PGE2)-stimulated aggregation of neutrophil-like HL-60 cells has been investigated. Although the EP2 receptors appear to couple to Gs-proteins, PGE2 stimulated HL-60 cell aggregation appears to be a cAMP-independent process. This response to PGE2 in independent of calcium and tyrosine kinase activity, appears to involve activation of phosphatidylinositol 3-kinase which is negatively regulated by phosphatidic acid generated from phospholipase D activity, and is partially dependent on protein kinase C activity. In contrast, although the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) produces a similar aggregation response to PGE2, FMLP uses a distinct intracellular signalling pathway. The aggregation response to FMLP involves activation of Gi-proteins, is partially dependent on extracellular calcium, is negatively regulated by protein kinase C, and is independent of phosphatidylinositol 3-kinase, phospholipase D and tyrosine kinase activity. The possibility exists that EP2 receptor activation leads to Gs-dependent, but cAMP-independent, stimulation of phosphatidylinositol 3-kinase activity in HL-60 cells.
References
Sep 1, 1978·The American Journal of Physiology·K M BaldwinR E Lewis
Apr 1, 1979·The Journal of Experimental Medicine·S J CollinsR C Gallo
May 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·S J CollinsR C Gallo
Jan 1, 1992·International Archives of Allergy and Immunology·S NagataM M Glovsky
Jun 15, 1992·European Journal of Biochemistry·M CampsP Gierschik
May 10, 1991·Science·M I SimonN Gautam
Nov 1, 1990·The Journal of Allergy and Clinical Immunology·C P NielsonR Heaslip
Apr 1, 1990·Naunyn-Schmiedeberg's Archives of Pharmacology·G HeckerK Schrör
Jan 22, 1987·Nature·D E LogothetisD E Clapham
Jan 1, 1989·British Journal of Pharmacology·P Ney, K Schrör
Sep 1, 1989·The Biochemical Journal·G MilliganM J Wakelam
Apr 1, 1985·Journal of Leukocyte Biology·P Harris, P Ralph
Oct 1, 1985·The Journal of Clinical Investigation·K H KrauseP D Lew
Jul 15, 1994·European Journal of Pharmacology·R J Williams, E Kelly
Oct 4, 1995·Biochemical and Biophysical Research Communications·R LauenerH Salari
Oct 27, 1995·The Journal of Biological Chemistry·M J CrossM J Wakelam
Apr 1, 1995·British Journal of Pharmacology·E TalpainC J Vardey
Oct 1, 1994·British Journal of Pharmacology·H Wise, R L Jones
Jul 18, 1994·Biochimica Et Biophysica Acta·M J Fry
May 24, 1994·Proceedings of the National Academy of Sciences of the United States of America·M ThelenH Langen
Apr 1, 1993·British Journal of Pharmacology·A Wheeldon, C J Vardey
Sep 30, 1993·Nature·D E Clapham, E J Neer
Dec 1, 1995·British Journal of Pharmacology·R A Armstrong
Aug 2, 1996·The Journal of Biological Chemistry·B T Liang, J F Morley
Oct 1, 1995·Journal of Lipid Mediators and Cell Signalling·M NegishiA Ichikawa
May 1, 1996·Prostaglandins, Leukotrienes, and Essential Fatty Acids·H Wise
Mar 1, 1996·Prostaglandins, Leukotrienes, and Essential Fatty Acids·H Wise, Z H Xie
Oct 1, 1996·Journal of Leukocyte Biology·H Wise
Jul 21, 2011·Journal of Nanoscience and Nanotechnology·M K HongJ H Kim
Citations
Mar 26, 2005·Prostaglandins & Other Lipid Mediators·Filippo Renò, Mario Cannas
Nov 1, 2005·Biochemical and Biophysical Research Communications·Susanne RöschBurkhard Hinz
May 23, 2001·Trends in Cardiovascular Medicine·S O OlofssonL Asp
Nov 10, 2009·American Journal of Physiology. Lung Cellular and Molecular Physiology·Mirella ProfitaMark Gjomarkaj